Cargando…

Long‐Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity

INTRODUCTION: OnabotulinumtoxinA treatment for spasticity varies according to numerous factors and is individualized to meet treatment goals. OBJECTIVE: To explore real‐world onabotulinumtoxinA utilization and effectiveness in patients with lower limb spasticity from the Adult Spasticity Internation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esquenazi, Alberto, Bavikatte, Ganesh, Bandari, Daniel S., Jost, Wolfgang H., Munin, Michael C., Tang, Simon Fuk Tan, Largent, Joan, Adams, Aubrey Manack, Zuzek, Aleksej, Francisco, Gerard E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519010/ https://www.ncbi.nlm.nih.gov/pubmed/33151636 http://dx.doi.org/10.1002/pmrj.12517

Ejemplares similares

Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician‐ and Patient‐Reported Satisfaction: Long‐Term Observational Results from the ASPIRE Study
por: Francisco, Gerard E., et al.
Publicado: (2020)

High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study
por: Francisco, Gerard E., et al.
Publicado: (2020)

Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Esquenazi, Alberto, et al.
Publicado: (2023)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review
por: Nalysnyk, Luba, et al.
Publicado: (2013)

AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol
por: Esquenazi, Alberto, et al.
Publicado: (2021)

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
por: Matharu, Manjit, et al.
Publicado: (2017)

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
por: Blumenfeld, Andrew M., et al.
Publicado: (2018)

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study
por: Young, William B., et al.
Publicado: (2019)

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019)

OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity
por: De Icco, Roberto, et al.
Publicado: (2019)

Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial
por: Devier, Deidre, et al.
Publicado: (2017)

OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients
por: Gfrerer, Lisa, et al.
Publicado: (2021)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Rothrock, John F., et al.
Publicado: (2019)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE
por: Agarwal, Pinky, et al.
Publicado: (2022)

Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
por: Winner, Paul K., et al.
Publicado: (2019)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update
por: Brin, Mitchell F., et al.
Publicado: (2023)

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
por: Young, William B., et al.
Publicado: (2019)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)
por: Charles, P. David, et al.
Publicado: (2014)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
por: Ayyoub, Ziyad, et al.
Publicado: (2020)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Gormley, Mark, et al.
Publicado: (2023)

Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial
por: Dimitrova, Rozalina, et al.
Publicado: (2021)

Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study
por: Patel, Atul T., et al.
Publicado: (2020)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nt0v1d62vid93f5nqr79a11g3b